{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2&page=26",
    "query": {
      "intervention": "Phase 2",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 37500,
    "total_pages": 3750,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+2&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T05:38:35.152Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07412756",
      "title": "A Study of Brenipatide in Adult Participants With Major Depressive Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "Brenipatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2026-02-09",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-28T05:38:35.152Z",
      "location_count": 32,
      "location_summary": "Moorpark, California • Orange, California • New Haven, Connecticut + 29 more",
      "locations": [
        {
          "city": "Moorpark",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07412756"
    },
    {
      "nct_id": "NCT02173522",
      "title": "Phase II Investigation of Prostate Artery Embolization (PAE) Before Radical Prostatectomy in Prostate Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Prostate artery embolization (PAE)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Shivank Bhatia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "79 Years",
        "sex": "MALE",
        "summary": "45 Years to 79 Years · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2014-07",
      "completion_date": "2017-06-16",
      "has_results": true,
      "last_update_posted_date": "2019-06-25",
      "last_synced_at": "2026-10-28T05:38:35.152Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02173522"
    },
    {
      "nct_id": "NCT03321929",
      "title": "Intraoperative Detection of Residual Cancer in Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "LUM Imaging System",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Lumicell, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 234,
      "start_date": "2018-02-06",
      "completion_date": "2020-04-10",
      "has_results": true,
      "last_update_posted_date": "2023-05-01",
      "last_synced_at": "2026-10-28T05:38:35.152Z",
      "location_count": 16,
      "location_summary": "Mobile, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03321929"
    },
    {
      "nct_id": "NCT02824029",
      "title": "Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Classical Hodgkin Lymphoma",
        "Recurrent Hodgkin Lymphoma",
        "Refractory Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2016-06",
      "completion_date": "2025-01-08",
      "has_results": true,
      "last_update_posted_date": "2025-02-17",
      "last_synced_at": "2026-10-28T05:38:35.152Z",
      "location_count": 4,
      "location_summary": "Ann Arbor, Michigan • Detroit, Michigan • Knoxville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02824029"
    },
    {
      "nct_id": "NCT00275431",
      "title": "Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Follicular Lymphoma",
        "Diffuse Large Cell Lymphoma",
        "Mantle Cell Lymphoma",
        "Small Lymphocytic Lymphoma",
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "AT-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ascenta Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2005-11",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2011-06-29",
      "last_synced_at": "2026-10-28T05:38:35.152Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • San Diego, California • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00275431"
    },
    {
      "nct_id": "NCT01887002",
      "title": "Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Irritable Bowel Syndrome (IBS)"
      ],
      "interventions": [
        {
          "name": "ONO-2952",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ono Pharma USA Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 39,
      "start_date": "2013-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-02-25",
      "last_synced_at": "2026-10-28T05:38:35.152Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • St Louis, Missouri • Chapel Hill, North Carolina + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01887002"
    },
    {
      "nct_id": "NCT01234337",
      "title": "Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Sorafenib (Nexavar, BAY43-9006)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 537,
      "start_date": "2011-02-21",
      "completion_date": "2017-10-20",
      "has_results": true,
      "last_update_posted_date": "2018-11-06",
      "last_synced_at": "2026-10-28T05:38:35.152Z",
      "location_count": 19,
      "location_summary": "Greenbrae, California • Sylmar, California • West Palm Beach, Florida + 15 more",
      "locations": [
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Sylmar",
          "state": "California"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Joliet",
          "state": "Illinois"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01234337"
    },
    {
      "nct_id": "NCT01515124",
      "title": "The Women In Steady Exercise Research (WISER) Survivor Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lymphedema"
      ],
      "interventions": [
        {
          "name": "Exercise Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Weight Loss Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "Up to 80 Years · Female only"
      },
      "enrollment_count": 450,
      "start_date": "2012-01",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2022-10-10",
      "last_synced_at": "2026-10-28T05:38:35.152Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01515124"
    },
    {
      "nct_id": "NCT00730262",
      "title": "Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "TLN-4601",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thallion Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2008-08",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2009-12-30",
      "last_synced_at": "2026-10-28T05:38:35.152Z",
      "location_count": 2,
      "location_summary": "New York, New York • Durham, North Carolina",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00730262"
    },
    {
      "nct_id": "NCT06627088",
      "title": "A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "LY4100511 (DC-853)",
          "type": "DRUG"
        },
        {
          "name": "[14C]-LY4100511 (DC-853) Administered oral dose",
          "type": "DRUG"
        },
        {
          "name": "[14C]-LY4100511 (DC-853)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 24,
      "start_date": "2024-08-23",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-01-24",
      "last_synced_at": "2026-10-28T05:38:35.152Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06627088"
    }
  ]
}